Can MTHFR A1298C heterozygosity mildly reduce methylation efficiency?

MTHFR A1298C heterozygosity is best viewed as a modest modifier of one-carbon metabolic reserve, not as evidence by itself of clinically meaningful “methylation impairment.” Its potential relevance increases when measured homocysteine is elevated in a setting that limits remethylation capacity.

Clinical and biochemical evidence

• AC carriers have approximately 80–85% of reference MTHFR activity, plausibly modestly constraining formation of 5-methyltetrahydrofolate and methionine remethylation.
• This enzymatic difference has not produced a consistent measurable phenotype in isolated AC carriers. Meta-analytic evidence found no significant homocysteine difference from AA carriers (+0.55 μmol/L, 95% CI −0.72 to 1.82) and no significant blood-folate difference.
• A meta-analysis of global genomic methylation found no association with A1298C. Limited SAM:SAH data and individual DNA-methylation studies are likewise inconsistent.

Mechanistic context

• Folate supplies 5-methyl-THF, while vitamin B12 is required for methionine synthase; insufficiency of either can impair remethylation and raise homocysteine. Riboflavin, vitamin B6, renal function, metabolic status, and concurrent C677T genotype also influence this pathway.
• Higher homocysteine can increase S-adenosylhomocysteine (SAH). SAH inhibits SAM-dependent methyltransferases and lowers the SAM:SAH ratio, creating a credible biochemical route to less favorable methylation capacity, including impaired DNA methylation.

Clinical interpretation

• For this 52-year-old man, an AC result alone does not establish reduced methylation efficiency, elevated homocysteine, or a need to infer one-carbon dysfunction. Its practical significance depends on direct biochemical and nutritional context rather than genotype alone.

Bottom line

• A1298C heterozygosity may mildly reduce pathway reserve, particularly during cofactor or metabolic stress; elevated homocysteine makes SAH-mediated methyltransferase inhibition biologically plausible, but neither impaired methylation nor its clinical magnitude should be assumed from AC status alone.